Johnson & Johnson (JNJ)
| Market Cap | 424.62B |
| Revenue (ttm) | 89.19B |
| Net Income (ttm) | 17.77B |
| Shares Out | 2.63B |
| EPS (ttm) | 6.65 |
| PE Ratio | 24.25 |
| Forward PE | 15.31 |
| Dividend | $4.09 (2.54%) |
| Ex-Dividend Date | Aug 23, 2021 |
| Volume | 6,918,407 |
| Open | 161.03 |
| Previous Close | 160.11 |
| Day's Range | 160.41 - 161.81 |
| 52-Week Range | 130.31 - 178.93 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 188.88 (+17.1%) |
| Est. Earnings Date | Oct 19, 2021 |
About JNJ
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the S...
Financial Performance
In 2020, JNJ's revenue was $82.58 billion, an increase of 0.64% compared to the previous year's $82.06 billion. Earnings were $14.71 billion, a decrease of -2.68%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 188.88, which is an increase of 17.10% from the latest price.
News
Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?
It's highly likely.
The Safest Stocks to Buy if There's a Stock Market Crash
This stock trio is perfectly positioned to help investors navigate a possible downturn.
What to expect after the FDA's approval of the J&J booster
#J&Jbooster With the FDA's advisory panel unanimously approving booster shots of the J&J vaccine two months after the first dose, Dr. Lakshman Swamy, ICU physician at Cambridge Health Alliance & Boston ...
Into the Heart of Q3 Earnings Season
The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporti...
We're at a very delicate time in this pandemic: FDA advisory panel member
Dr. Ofer Levy, a voting member of the FDA vaccine advisory panel, joins Closing Bell to discuss the panel's decision to recommend a booster dose of Johnson & Johnson's Covid vaccine.
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA A...
NEW BRUNSWICK, N.J., Oct. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advi...
FDA panel backs J&J Covid-19 vaccine booster shot for people 18 years and older
#J&Jvaccine Yahoo Finance's Alexis Christoforous reports the latest FDA decision on COVID-19 boosters. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb...
FDA panel recommends Johnson & Johnson COVID booster for people 18 and up
The advisers unanimously voted that those who got the one-dose vaccine should get a booster at least two months later.
FDA Advisory Committee Recommends Booster Shots Of J&J Vaccine For People 18 And Older
The recommendation of the independent panel of experts is typically followed by the FDA.
Explained here why Johnson & Johnson is setting a $2 billion trust
Johnson & Johnson (NYSE: JNJ) put its obligations for tens of thousands of cases tying talc-based products to cancer into bankruptcy. The company hopes the action will help push a personal injury claims...
Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?
The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.
Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme
CHARLOTTE, N.C., Oct. 14, 2021 /PRNewswire/ -- Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powder...
J&J unit to manage talc claims files for bankruptcy protection
Johnson & Johnson said on Thursday its newly created unit that was established to hold and manage claims in the Baby Powder litigation, has filed for voluntary Chapter 11 bankruptcy protection.
Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
NEW BRUNSWICK, N.J., Oct. 14, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson...
FDA advisors prepare to vote on Moderna, J&J Covid boosters
A group of expert FDA advisors plan to meet over the coming days to discuss Moderna's and Johnson & Johnson's applications for a Covid-19 booster. CNBC's Meg Tirrell reports.
J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study Finds
J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.
FDA Says J&J Covid Booster Likely Boosts Immunity, But Evidence Isn't Full-Proof
An advisory panel will review the argument for second Johnson & Johnson doses Friday.
3 Top Healthcare Stocks to Buy Right Now
Each has its own reason for being in your portfolio.
Got $1,000? 2 Super-Smart Stocks That Could Make You Richer Over the Next Decade
Here are two stocks to add to your basket of buys this fall.
Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
NEW BRUNSWICK, N.J., Oct. 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will hold a Business Review for the investment community on Thursday, November 18, 2021, in which company leaders will sh...
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $157.69, moving -1.6% from the previous trading session.